Writings OLD
December 1, 2022
Crimean-Congo Hemorrhagic Fever is among the deadliest diseases in the world; a tick-born disease touting a mortality rate of up to 40%. First discovered almost eight decades ago, there is no effective treatment at present. Here we describe a work in progress of attempts to develop monoclonal antibodies to prevent … read more
November 30, 2022
November 28, 2022
Here we describe the integration of CRISPR gene-editing technology to improve CAR T therapy design. Other alternative CAR T designs include and the . Previous installments discuss the and its applications for,, and the
CRISPR technology has advanced the field of genetic engineering, and could soon profoundly impact the world of CAR T therapy.
GETTY Researchers find … read moreNovember 23, 2022
Researchers from Duke University, UC Berkeley, Purdue University, and elsewhere have made what will likely be a significant breakthrough in drug development to treat Zika Virus infections. They discovered an unusual monoclonal antibody, not of the common immunoglobulin G family, but rather immunoglobulin M. This antibody is extraordinarily potent in … read more
November 20, 2022
Here we describe a recent research advancement that fine-tunes CAR T therapy. Previous installments discuss the and its applications for , , and the
People with treatment-resistant blood cancers turn to CAR T therapy, a recent medical innovation, for long-sought respite but can suffer potentially fatal side effects. … read more
November 15, 2022
A report by the United States Centers for Disease Control and Prevention (CDC) makes clear that vaccines can only protect us if we let them: just as protection from infection wanes over time, so too does protection against serious disease and hospitalization. The message is clear, if we want … read more
November 14, 2022
November 14, 2022
Monoclonal antibodies are among our greatest assets in treating and preventing virus-induced disease. While the spotlight has focused squarely on Covid-19 monoclonal antibodies throughout the pandemic, antibody candidates for other severe pathogens have also made strides forward. Here we describe a new antibody candidate that neutralizes a parasitic foe that … read more
November 12, 2022
This article is the fifth installment in my series on Alzheimer’s disease. Read more about Alzheimer’s disease in , , , and of the series.
In the last installment of my series on Alzheimer’s disease, I discussed a new experimental treatment for Alzheimer’s called lecanemab. This September, clinical … read more
November 7, 2022
This is the second of two articles on a temperature-sensitive self-replicating RNA vaccine; click here for part one. They form part of a broader series on next-generation mRNA vaccines. The first three installments can be read here, here, and read more